JP2014525435A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014525435A5 JP2014525435A5 JP2014527791A JP2014527791A JP2014525435A5 JP 2014525435 A5 JP2014525435 A5 JP 2014525435A5 JP 2014527791 A JP2014527791 A JP 2014527791A JP 2014527791 A JP2014527791 A JP 2014527791A JP 2014525435 A5 JP2014525435 A5 JP 2014525435A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- rnai agent
- hsf1
- nucleotides
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161530532P | 2011-09-02 | 2011-09-02 | |
| US61/530,532 | 2011-09-02 | ||
| US201261598453P | 2012-02-14 | 2012-02-14 | |
| US61/598,453 | 2012-02-14 | ||
| PCT/IB2012/054455 WO2013030778A2 (en) | 2011-09-02 | 2012-08-30 | Organic compositions to treat hsf1-related diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018168244A Division JP2019001813A (ja) | 2011-09-02 | 2018-09-07 | Ｈｓｆ１関連疾患を処置するための有機組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014525435A JP2014525435A (ja) | 2014-09-29 |
| JP2014525435A5 true JP2014525435A5 (cg-RX-API-DMAC10.html) | 2015-10-15 |
Family
ID=47143967
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014527791A Pending JP2014525435A (ja) | 2011-09-02 | 2012-08-30 | Ｈｓｆ１関連疾患を処置するための有機組成物 |
| JP2018168244A Pending JP2019001813A (ja) | 2011-09-02 | 2018-09-07 | Ｈｓｆ１関連疾患を処置するための有機組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018168244A Pending JP2019001813A (ja) | 2011-09-02 | 2018-09-07 | Ｈｓｆ１関連疾患を処置するための有機組成物 |
Country Status (11)
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2857499A1 (en) | 2010-10-01 | 2015-04-08 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| PT3682905T (pt) | 2011-10-03 | 2022-04-07 | Modernatx Inc | Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações |
| ES2923757T3 (es) | 2011-12-16 | 2022-09-30 | Modernatx Inc | Composiciones de ARNm modificado |
| WO2013151664A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| PT2922554T (pt) | 2012-11-26 | 2022-06-28 | Modernatx Inc | Arn modificado nas porções terminais |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| KR20160067219A (ko) | 2013-10-03 | 2016-06-13 | 모더나 세라퓨틱스, 인코포레이티드 | 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드 |
| GB201317609D0 (en) | 2013-10-04 | 2013-11-20 | Cancer Rec Tech Ltd | Inhibitor compounds |
| HRP20220070T1 (hr) | 2014-04-23 | 2022-04-01 | Modernatx, Inc. | Cjepiva nukleinske kiseline |
| GB201505658D0 (en) | 2015-04-01 | 2015-05-13 | Cancer Rec Tech Ltd | Inhibitor compounds |
| MA42502A (fr) | 2015-07-21 | 2018-05-30 | Modernatx Inc | Vaccins contre une maladie infectieuse |
| US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
| SG11201803360UA (en) | 2015-10-22 | 2018-05-30 | Modernatx Inc | Nucleic acid vaccines for varicella zoster virus (vzv) |
| MA45209A (fr) | 2015-10-22 | 2019-04-17 | Modernatx Inc | Vaccins contre les maladies sexuellement transmissibles |
| WO2017070624A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Tropical disease vaccines |
| GB201617103D0 (en) | 2016-10-07 | 2016-11-23 | Cancer Research Technology Limited | Compound |
| MA46766A (fr) | 2016-11-11 | 2019-09-18 | Modernatx Inc | Vaccin antigrippal |
| EP3551193A4 (en) | 2016-12-08 | 2020-08-19 | Modernatx, Inc. | NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES |
| WO2018170260A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Respiratory syncytial virus vaccine |
| WO2018170256A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Herpes simplex virus vaccine |
| US11576961B2 (en) | 2017-03-15 | 2023-02-14 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| WO2018170270A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Varicella zoster virus (vzv) vaccine |
| EP3681514A4 (en) | 2017-09-14 | 2021-07-14 | ModernaTX, Inc. | RNA VACZINE AGAINST ZIKA VIRUS |
| US11911453B2 (en) | 2018-01-29 | 2024-02-27 | Modernatx, Inc. | RSV RNA vaccines |
| US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
| MA55321A (fr) | 2019-03-15 | 2022-01-19 | Modernatx Inc | Vaccins à base d'arn contre le vih |
| US11095153B2 (en) | 2019-03-15 | 2021-08-17 | Ossia Inc. | Wireless power system technology implemented in lighting infrastructure |
| WO2021231678A1 (en) * | 2020-05-13 | 2021-11-18 | University Of Massachusetts | Reducing prominin2-mediated resistance to ferroptotic cell death |
| WO2022006436A2 (en) * | 2020-07-01 | 2022-01-06 | Bioaffinity Technologies, Inc. | Compositions and methods for cellular delivery of rna |
| CN119523991B (zh) * | 2024-12-06 | 2025-09-05 | 湖南师范大学 | 表木栓醇在制备抗肺癌物质中的用途和抗肺癌组合物 |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6696561B1 (en) | 1909-07-09 | 2004-02-24 | Basf Aktiengesellschaft | Corynebacterium glutamicum genes encoding proteins involved in membrane synthesis and membrane transport |
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US5030453A (en) | 1983-03-24 | 1991-07-09 | The Liposome Company, Inc. | Stable plurilamellar vesicles |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US5032401A (en) | 1989-06-15 | 1991-07-16 | Alpha Beta Technology | Glucan drug delivery system and adjuvant |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US6977244B2 (en) | 1996-10-04 | 2005-12-20 | Board Of Regents, The University Of Texas Systems | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
| US7053052B2 (en) | 1997-01-21 | 2006-05-30 | Voellmy Richard W | Therapies involving mutated heat shock transcription factor |
| US5891467A (en) | 1997-01-31 | 1999-04-06 | Depotech Corporation | Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
| AU776150B2 (en) | 1999-01-28 | 2004-08-26 | Medical College Of Georgia Research Institute, Inc. | Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| IL145778A0 (en) | 1999-04-21 | 2002-07-25 | American Home Prod | Methods and compositions for inhibiting the function of polynucleotide sequences |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| JP2003526367A (ja) | 2000-03-16 | 2003-09-09 | ジェネティカ インコーポレイテッド | Ｒｎａ干渉の方法とｒｎａ干渉組成物 |
| KR20080023768A (ko) | 2000-03-30 | 2008-03-14 | 화이트헤드 인스티튜트 포 바이오메디칼 리서치 | Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체 |
| US6680068B2 (en) | 2000-07-06 | 2004-01-20 | The General Hospital Corporation | Drug delivery formulations and targeting |
| WO2002100435A1 (en) | 2001-06-11 | 2002-12-19 | Centre Hospitalier Universitaire De Montreal | Compositions and methods for enhancing nucleic acid transfer into cells |
| US20030190312A1 (en) | 2001-06-22 | 2003-10-09 | The Regents Of The University Of California | Eukaryotic genes involved in adult lifespan regulation |
| WO2003015757A1 (en) | 2001-08-16 | 2003-02-27 | The Trustees Of The University Of Pennsylvania | Synthesis and use of reagents for improved dna lipofection and/or slow release prodrug and drug therapies |
| EP1519714B1 (en) | 2002-06-28 | 2010-10-20 | Protiva Biotherapeutics Inc. | Method and apparatus for producing liposomes |
| US20040029275A1 (en) * | 2002-08-10 | 2004-02-12 | David Brown | Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs |
| EP1658304A4 (en) | 2002-09-28 | 2009-01-14 | Massachusetts Inst Technology | THERAPY ANTIGRIPPALE |
| US7250496B2 (en) | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
| EP2305813A3 (en) | 2002-11-14 | 2012-03-28 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
| WO2004048545A2 (en) | 2002-11-26 | 2004-06-10 | University Of Massachusetts | DELIVERY OF siRNAs______________________________________________ |
| US20040208921A1 (en) | 2003-01-14 | 2004-10-21 | Ho Rodney J. Y. | Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymphoid tissues |
| AU2004257373B2 (en) | 2003-07-16 | 2011-03-24 | Arbutus Biopharma Corporation | Lipid encapsulated interfering RNA |
| CN1845993B (zh) | 2003-08-28 | 2010-06-23 | 诺瓦提斯公司 | 具有平端和3＇修饰的干扰rna双链体 |
| US7740861B2 (en) | 2004-06-16 | 2010-06-22 | University Of Massachusetts | Drug delivery product and methods |
| CA2603842A1 (en) | 2005-04-08 | 2006-10-19 | Nastech Pharmaceutical Company Inc. | Rnai therapeutic for respiratory virus infection |
| US8354384B2 (en) | 2005-06-23 | 2013-01-15 | Yale University | Anti-aging micrornas |
| WO2007041294A2 (en) * | 2005-09-29 | 2007-04-12 | The Trustees Of Boston University | Methods for sensitizing cancer cells to inhibitors |
| EP1948674A4 (en) | 2005-11-02 | 2009-02-04 | Protiva Biotherapeutics Inc | MODIFIED SIRNA MOLECULES AND APPLICATIONS THEREOF |
| US7919603B2 (en) | 2005-12-19 | 2011-04-05 | New York University | Heat shock RNA |
| ES2556128T3 (es) | 2006-03-23 | 2016-01-13 | Roche Innovation Center Copenhagen A/S | ARN interfiriente pequeño internamente segmentado |
| GB0608838D0 (en) | 2006-05-04 | 2006-06-14 | Novartis Ag | Organic compounds |
| WO2008022035A2 (en) | 2006-08-10 | 2008-02-21 | The Scripps Research Institute | Methods for identifying cellular modulators of disaggregation activity or aggregation activity in an animal |
| WO2008097840A2 (en) | 2007-02-02 | 2008-08-14 | Dana-Farber Cancer Institute, Inc. | Methods and compositions relating to the regulation of muc1 by hsf1 and stat3 |
| US7858592B2 (en) | 2007-02-26 | 2010-12-28 | The Board Of Regents Of The University Of Texas System | Interfering RNAs against the promoter region of P53 |
| WO2008141074A1 (en) | 2007-05-10 | 2008-11-20 | Salk Institute For Biological Studies | Identification of compounds that protect against amyloid diseases |
| NZ580712A (en) | 2007-05-22 | 2011-12-22 | Marina Biotech Inc | Hydroxymethyl substituted rna oligonucleotides and rna complexes containing acyclic monomers |
| AR066984A1 (es) | 2007-06-15 | 2009-09-23 | Novartis Ag | Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia) |
| US9006191B2 (en) | 2007-12-27 | 2015-04-14 | Protiva Biotherapeutics, Inc. | Silencing of polo-like kinase expression using interfering RNA |
| US8188060B2 (en) | 2008-02-11 | 2012-05-29 | Dharmacon, Inc. | Duplex oligonucleotides with enhanced functionality in gene regulation |
| WO2009103067A2 (en) | 2008-02-14 | 2009-08-20 | The Children's Hospital Of Philadelphia | Compositions and methods to treat asthma |
| WO2010135669A1 (en) * | 2009-05-22 | 2010-11-25 | Sabiosciences Corporation | Arrays and methods for reverse genetic functional analysis |
| CA2776796C (en) | 2009-10-16 | 2018-11-13 | University Health Network | Porphyrin nanovesicles |
| MX339050B (es) | 2009-12-18 | 2016-05-09 | Novartis Ag | Composiciones organicas para tratar las enfermedades relacionadas con hsf1. |
| KR101733096B1 (ko) | 2015-09-25 | 2017-05-24 | 강건우 | 전자레인지용 밥솥 |
-
2012
- 2012-08-30 US US14/342,193 patent/US20160032284A1/en not_active Abandoned
- 2012-08-30 BR BR112014005103A patent/BR112014005103A2/pt not_active IP Right Cessation
- 2012-08-30 EP EP12783287.1A patent/EP2751272A2/en not_active Withdrawn
- 2012-08-30 EP EP19161727.3A patent/EP3521432A1/en not_active Withdrawn
- 2012-08-30 CA CA3185394A patent/CA3185394A1/en active Pending
- 2012-08-30 EP EP16179166.0A patent/EP3098314B1/en active Active
- 2012-08-30 WO PCT/IB2012/054455 patent/WO2013030778A2/en not_active Ceased
- 2012-08-30 JP JP2014527791A patent/JP2014525435A/ja active Pending
- 2012-08-30 CA CA2847283A patent/CA2847283C/en active Active
- 2012-08-30 EA EA201490553A patent/EA201490553A1/ru unknown
- 2012-08-30 CN CN201280053243.0A patent/CN103930547A/zh active Pending
- 2012-08-30 KR KR1020147008647A patent/KR20140057374A/ko not_active Withdrawn
- 2012-08-30 MX MX2014002536A patent/MX2014002536A/es unknown
-
2016
- 2016-04-18 AU AU2016202437A patent/AU2016202437B2/en not_active Ceased
-
2017
- 2017-05-05 US US15/587,538 patent/US10329563B2/en active Active
-
2018
- 2018-09-07 JP JP2018168244A patent/JP2019001813A/ja active Pending
-
2019
- 2019-06-24 US US16/450,967 patent/US20190323008A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015517466A5 (cg-RX-API-DMAC10.html) | ||
| Gurunathan et al. | A comprehensive review on factors influences biogenesis, functions, therapeutic and clinical implications of exosomes | |
| Fang et al. | Macrophage-targeted hydroxychloroquine nanotherapeutics for rheumatoid arthritis therapy | |
| Douglas et al. | Splicing therapy for neuromuscular disease | |
| Gorantla et al. | Targeted drug-delivery systems in the treatment of rheumatoid arthritis: recent advancement and clinical status | |
| JP2015503608A5 (cg-RX-API-DMAC10.html) | ||
| Lembo et al. | Nanoparticulate delivery systems for antiviral drugs | |
| JP2013514321A5 (cg-RX-API-DMAC10.html) | ||
| JP2016511256A5 (cg-RX-API-DMAC10.html) | ||
| Huang et al. | Orally targeted galactosylated chitosan poly (lactic-co-glycolic acid) nanoparticles loaded with TNF-ɑ siRNA provide a novel strategy for the experimental treatment of ulcerative colitis | |
| He et al. | Multifunctional polymeric nanoparticles for oral delivery of TNF-α siRNA to macrophages | |
| JP2023093644A (ja) | アンジオテンシノーゲンの発現を調節するための化合物及び方法 | |
| Cheng et al. | T7 peptide-conjugated lipid nanoparticles for dual modulation of Bcl-2 and Akt-1 in lung and cervical carcinomas | |
| Giger et al. | Biomedical applications of bisphosphonates | |
| JP2022115999A (ja) | 浮遊病原体および刺激物に対して防御するための組成物および方法 | |
| AU2013208720A1 (en) | RNAi agents to treat Beta-Catenin related diseases | |
| CN104884065A (zh) | 治疗癌症的方法 | |
| JP6944942B2 (ja) | ＩＬ４Ｒα、ＴＲＰＡ１、またはＦ２ＲＬ１を標的とするＲＮＡ複合体を用いたアトピー性皮膚炎および喘息の治療 | |
| JP2015516989A5 (cg-RX-API-DMAC10.html) | ||
| JP2014518275A5 (cg-RX-API-DMAC10.html) | ||
| JP2012530715A5 (cg-RX-API-DMAC10.html) | ||
| JP2019503199A5 (cg-RX-API-DMAC10.html) | ||
| JP2020094073A (ja) | 皮膚Ｔ細胞リンパ腫（ＣＴＣＬ）を処置するためのｍｉＲ−１５５阻害剤 | |
| JP2014528474A5 (cg-RX-API-DMAC10.html) | ||
| AR079494A1 (es) | Composiciones organicas para tratar las enfermedades relacionadas con el factor de choque por calor 1 hsf1 |